Selling serialization data could help recuperate costs, says Medicines for Europe exec

By Flora Southey contact

- Last updated on GMT

Selling information from Europe’s national data repositories could help recover serialisation costs, says Medicines for Europe’s Johan Verhaeghe.

Marketing authorisation holder (MAH) data uploaded to national data banks via Europe’s central data router – known as the EU Hub​ – has enormous potential value, the organisation’s national policy liaison told us at the Adents Serialization Innovation Summit last week.

Belgian-based European Medicines Verification Organisation (EMVO) set up the EU Hub in response to the 2011 Falsified Medicines Directive​ (FMD), which comes into effect on February 9, 2019.

The directive is designed to help European supply chain stakeholders prevent fake medicines entering the supply chain by ensuring the “implementation of functioning, secure, interoperable and cost effective system across Europe.”

According to Verhaeghe, all stakeholders could benefit from commercialising national repository data: “From the beginning, we have been saying ‘why not look at other uses for the data?”

Companies regularly buy data reports from contract research organisation (CRO) IQVIA, so “if we can reduce costs by adding extra income from this system, then why not?”​ he told us.

While of course the cost of serialisation serves a purpose, industry cannot recuperate costs by raising drug prices, he explained.

“What we are saying, is if all supply chain stakeholder of the different aspects of the data commonly agree, it’s possible to use the data in other ways.”

Related news

Show more

Related products

show more

A Culture of Innovation as a Differentiation

A Culture of Innovation as a Differentiation

Softigel by Procaps | 06-Dec-2021 | Product Presentation

We create safe, effective and differentiated pharmaceutical solutions and this has been our goal since day 1. The main driver of our growth is innovation...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Follow us


View more